Journal: Oncology Letters

Article Title: Bone sialoprotein stimulates cancer cell adhesion through the RGD motif and the αvβ3 and αvβ5 integrin receptors

doi: 10.3892/ol.2024.14675

Figure Lengend Snippet: Effect of anti-αvβ3 or anti-αvβ5 antibody on cancer cell adhesion to BSP, as determined by the alamarBlue ® assay. (A) MDA-MB-231 (n=4), (B) PC-3 (n=4) and (C) NCI-H460 (n=4) cells were incubated for 60 min at 37°C in the presence of 10 µg/ml isotype control IgG1, 10 µg/ml anti-αvβ3 antibody or 10 µg/ml anti-αvβ5 antibody. Afterwards, cells were cultured for 2 h on BSP-coated plates and attached cells were examined. Data are reported as percentages compared with 10 µg/ml isotype control IgG1 (100%). Error bars represent the standard deviation. **P<0.01; ****P<0.0001 vs. negative control IgG1. BSP, bone sialoprotein; ns, not significant.

Article Snippet: Anti-integrin αvβ3 mouse monoclonal antibody, (clone LM609; catalogue no. MAB1976Z) and anti-integrin αvβ5 mouse monoclonal antibody (clone P1F6; catalogue no. MAB1961Z) were obtained from Millipore (Merck KGaA).

Techniques: Alamar Blue Assay, Incubation, Control, Cell Culture, Standard Deviation, Negative Control

Journal: Heliyon

Article Title: Fibronectin promotes tumor progression through integrin αvβ3/PI3K/AKT/SOX2 signaling in non-small cell lung cancer

doi: 10.1016/j.heliyon.2023.e20185

Figure Lengend Snippet: FN promotes tumor growth through integrin αvβ3. ( A) The relative expression of integrin αv, αII, α8 and α5 in FN-treated or untreated A549 cells and Lewis cells for 72 h at the mRNA level. (B) The relative gene expression of integrin β3, β5, β6 and β8 in FN-treated or untreated A549 and Lewis cells for 72 h. (C) Western blot of integrin αvβ3 in A549 and Lewis cells treated or untreated with FN for 72 h. (D) Relative cell proliferation of A549 and Lewis cells treated with PBS, FN or FN plus CT for 72 h. (E) The NSCLC tumor weight of mice. A total of 1 × 10 6 A549 and Lewis cells pretreated with PBS or FN or FN plus CT for 72 h were intratracheally instilled into nude mice. Tumor weight was calculated on day 20 and day 15 respectively. (F) Relative colony numbers and representative images of A549 and Lewis cells treated with PBS, FN or FN plus CT for 72 h. The scale bar is 30 μm. (G) The tumorigenesis of nude mice intratracheally instilled with 1 × 10 5 A549 cells and Lewis cells pretreated with PBS, FN or FN plus CT for 72 h. (H) Immunofluorescence of integrin αvβ3 in tumor tissues of high malignant or low malignant NSCLC patients. Scale bar, 20 μm. Error bar, mean ± SEM; * P < 0.05; ** P < 0.01; ns, not statistically significant. Cilengitide, CT.

Article Snippet: The sections were then blocked with 5% BSA and incubated with mouse monoclonal anti-integrin αvβ3 (1:100, ab7166, Abcam, UK), rabbit monoclonal SOX2 (1:200, ab92494, Abcam, Cambridge, UK), rabbit polyclonal p-AKT (1:200, ab38449, Abcam, Cambridge, UK), rabbit monoclonal KLF (1:200, ab215036, Abcam, Cambridge, UK), rabbit monoclonal total-PI3K (1:500, ab302958, Abcam, Cambridge, UK), mouse monoclonal CD90 (1:100, ab181496, Abcam, Cambridge, UK) for 4 °C overnight, and followed by horse radish peroxidase (HRP) conjugated secondary antibodies (1:600; Abcam, Cambridge, UK), and the nucleus was stained with DAPI.

Techniques: Expressing, Western Blot, Immunofluorescence

Journal: Heliyon

Article Title: Fibronectin promotes tumor progression through integrin αvβ3/PI3K/AKT/SOX2 signaling in non-small cell lung cancer

doi: 10.1016/j.heliyon.2023.e20185

Figure Lengend Snippet: Combination of integrin αvβ3 inhibitor and chemotherapeutic agents enhances anticancer effects in NSCLC treatment. ( A) The tumor weight analysis of lung tissues from mice on day 35 after intratracheally instillation withA549 cells and treatment with PBS, PTX or PTX combined with CT. (B) The survival time of A549-bearing mice treated with PBS, PTX or PTX combined with CT. (C) The NSCLC tumor weight of mice on day 35 after intratracheally instillation with A549 cells and treatment with PBS, MTX or MTX combined with CT. (D) The survival time of A549-bearing mice treated with PBS, MTX or MTX combined with CT. (E) The NSCLC tumor weight of mice on day 25 after intratracheally instillation with Lewis cells and treatment with PBS, PTX or PTX combined with CT. (F) The survival time of Lewis-bearing mice treated with PBS, PTX or PTX combined with CT. (G) The FN-treated NSCLC tumor weight of mice on day 35 after intratracheally instillation with 1 × 10 6 A549 cells and treatment with PBS, PTX or PTX combined with CT. (H) The survival time of FN-treated A549 bearing mice treated with PBS, PTX or PTX combined with CT. Error bars, mean ± SEM; * P < 0.05; ** P < 0.01; ns, not statistically significant. Cilengitide, CT.

Article Snippet: The sections were then blocked with 5% BSA and incubated with mouse monoclonal anti-integrin αvβ3 (1:100, ab7166, Abcam, UK), rabbit monoclonal SOX2 (1:200, ab92494, Abcam, Cambridge, UK), rabbit polyclonal p-AKT (1:200, ab38449, Abcam, Cambridge, UK), rabbit monoclonal KLF (1:200, ab215036, Abcam, Cambridge, UK), rabbit monoclonal total-PI3K (1:500, ab302958, Abcam, Cambridge, UK), mouse monoclonal CD90 (1:100, ab181496, Abcam, Cambridge, UK) for 4 °C overnight, and followed by horse radish peroxidase (HRP) conjugated secondary antibodies (1:600; Abcam, Cambridge, UK), and the nucleus was stained with DAPI.

Techniques: